MSC治疗改善了实验性痛风性关节炎,暗示了早期的COX-2诱导
Juan Pablo Medina1, Ismael Bermejo-Álvarez1, Sandra Pérez-Baos1
1Bone and Joint Research Unit, Rheumatology Dept, IIS-Fundación Jiménez Díaz Universidad Autonoma de Madrid (UAM), Madrid, Spain.
Frontiers in immunology
|August 3, 2023
概括
脂质衍生性介质干细胞 (Ad-MSC) 通过抑制NLRP3炎症体并促进抗炎反应,有效地减少了子的急性关节炎症. 这表明Ad-MSC治疗是治疗痛风性关节炎的潜在治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 痛风性关节炎涉及由单酸盐 (MSU) 水晶沉积和NLRP3炎症酶激活驱动的急性关节炎症.
- 在急性关节炎症中,特别是与先天性免疫有关的脂肪衍生性介质干细胞 (Ad-MSC) 的作用需要进一步阐明.
研究的目的:
- 研究人类Ad-MSC对子MSU诱导的急性关节炎的治疗效果.
- 探索Ad-MSCs调节炎症反应的潜在分子机制.
主要方法:
- 在子的关节内MSU晶体注射后,Ad-MSCs被静脉内注射.
- 局部和全身炎症标志物,NLRP3炎症酶激活和炎症介质合成在突膜中进行了评估.
- 在Ad-MSCs和MSU刺激的巨细胞的体外共同培养系统被利用.
主要成果:
- 一次系统剂量的Ad-MSC加速了局部和全身炎症的解决.
- 广告-MSCs促进了M2巨细胞在突中的偏离,抑制了NLRP3炎症酶激活,并降低了NF-κB活性.
- 在体外,Ad-MSCs诱导了净抗炎作用,增加了IL-10和IDO表达,同时减少了IL-1β和TNF.
结论:
- 通过抑制NLRP3炎症酶和促进M2巨细胞,Ad-MSC有效地减轻了急性关节炎症.
- 治疗效果包括早期的COX-2上调和PGE2释放,以及NF-κB抑制.
- 广告MSC治疗为痛风性关节炎提供了一个有前途的药理替代方案,特别是在对常规治疗有禁忌的患者中.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
500
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
500
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215


